Keywords: Eli Lilly, FDA advisory panel, Cymbalta, Antidepressant, Pain, ADHD, Strattera, Court ruling

US FDA advisory panel narrowly votes to expand use of Eli Lilly’s Cymbalta for pain

Article | 20 August 2010

Print This

In a decision that was not widely expected given ongoing liver damage concerns, a US Food and Drug Administration advisory ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in